A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Principal Investigator

Kim-Hien Dao

Study Purpose

This study is for subjects with myelofibrosis. There are 2 Parts to this Study: Part 1 and Part 2. The main purpose of Part 1 of this study is to test any good and bad effects of the study drug called INCB050465 in combination with ruxolitinib. Part 1 of this study will also test different doses of the drug to see which dose would be most appropriate for Part 2 of this study. The main purpose of Part 2 of this study is to find out if the study drug when given in combination with ruxolitinib treatment will positively impact spleen size and symptoms associated with your medical condition.

Medical Condition(s)

Primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) and post-essential thrombocythemia-myelofibrosis (PET-MF)

Eligibility Criteria

Eligible subjects must meet the following:
-Be at least 18 years or older,
-Have been diagnosed with PMF, PPV-MF, or PET-MF, and
-You have been treated with ruxolitinib for at least 6 months

Age Range

18 - n/a

Healthy Volunteers Needed


Duration of Participation

24 months

Minors Included



Clinical Trials Information Line
Phone: 503-494-1080


Incyte Corporation

Recruitment End


Compensation Provided


Go Back